Clinical Trial Update: Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression [Phase 4]

View source ↗

Summary

Phase 4 study comparing the olanzapine/fluoxetine fixed-dose combination (Symbyax) to a comparator for bipolar I depression has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Symbyax (olanzapine and fluoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Bipolar Disorder | Phase 4 | Status: COMPLETED